Hikma Pharmaceuticals PLC

LSE HIK.L

Hikma Pharmaceuticals PLC EPS (Diluted) for the year ending December 31, 2023: USD 0.85

Hikma Pharmaceuticals PLC EPS (Diluted) is USD 0.85 for the year ending December 31, 2023, a 1.19% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
  • Hikma Pharmaceuticals PLC EPS (Diluted) for the year ending December 31, 2022 was USD 0.84, a -53.59% change year over year.
  • Hikma Pharmaceuticals PLC EPS (Diluted) for the year ending December 31, 2021 was USD 1.81, a 0.00% change year over year.
  • Hikma Pharmaceuticals PLC EPS (Diluted) for the year ending December 31, 2020 was USD 1.81, a -9.50% change year over year.
  • Hikma Pharmaceuticals PLC EPS (Diluted) for the year ending December 31, 2019 was USD 2.00, a 70.94% change year over year.
Key data
Date EPS (Diluted) Shares (Diluted, Weighted) Shares (Basic, Weighted) Revenue
Market news
Loading...
SV Wall Street
LSE: HIK.L

Hikma Pharmaceuticals PLC

CEO Mr. Riad Ali Mishlawi
IPO Date Nov. 1, 2005
Location United Kingdom
Headquarters 1 New Burlington Place
Employees 9,100
Sector Health Care
Industries
Description

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Similar companies

ITRK.L

Intertek Group plc

USD 63.08

0.02%

BNZL.L

Bunzl plc

USD 42.50

0.02%

HLMA.L

Halma plc

USD 37.46

2.30%

SN.L

Smith & Nephew plc

USD 12.72

-0.22%

MNDI.L

Mondi plc

USD 15.27

1.47%

StockViz Staff

January 30, 2025

Any question? Send us an email